Anticancer activity of oxovanadium compounds

Cytotoxic and antitumor activities of the biligand vanadyl derivative of L-malic acid, (bis-(L-malato)oxovanadium(IV) (VO(mal) 2 ), the inorganic vanadium(IV) compound, vanadyl sulfate (VOSO 4 ), the oxovanadium monocomplex with L-malic acid (VO(mal)), and the vanadyl biscomplex with acetylacetonate...

Full description

Saved in:
Bibliographic Details
Published in:Biochemistry (Moscow). Supplement. Series B, Biomedical chemistry Biomedical chemistry, 2012-04, Vol.6 (2), p.164-170
Main Authors: Abakumova, O. Yu, Podobed, O. V., Belayeva, N. F., Tochilkin, A. I.
Format: Article
Language:English
Subjects:
Apoptosis
Biochemistry
Bioorganic Chemistry
Cancer
Cell culture
Chemistry
Chemistry and Materials Science
Medicinal Chemistry
Trace elements
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Cytotoxic and antitumor activities of the biligand vanadyl derivative of L-malic acid, (bis-(L-malato)oxovanadium(IV) (VO(mal) 2 ), the inorganic vanadium(IV) compound, vanadyl sulfate (VOSO 4 ), the oxovanadium monocomplex with L-malic acid (VO(mal)), and the vanadyl biscomplex with acetylacetonate (VO(acac) 2 ) were investigated using several tumor cell lines: mouse fibrosarcoma (L929), rat pheochromocytoma (PC12), human liver carcinoma (HepG2), mouse embryonic fibroblasts (NIH/3T3), and also normal human skin fibroblasts. The results showed that VO(mal) 2 effectively inhibited growth of cancer cell cultures without any toxic effect on normal human skin fibroblasts. The cytotoxic anticancer effect of vanadium complexes depended on concentration of the compounds studied, incubation time, types of cell cultures, and nature of ligands surrounding the central group of the complex (VO 2+ ). These studies provide evidence that VO(mal) 2 may be considered as a potential anticancer agent due to its low toxicity for non-tumor cells and significant anticancer activity.
ISSN:1990-7508
1990-7516
DOI:10.1134/S1990750812020023